A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF VX-880 IN SUBJECTS WHO HAVE TYPE 1 DIABETES MELLITUS WITH IMPAIRED HYPOGLYCEMIC AWARENESS AND SEVERE HYPOGLYCEMIA

Registry ID

VX20-880-101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

VERTEX PHARMACEUTICALS INC

Start date

2023-09-11

Last update

2021-08-27

Conditions

• HYPOGLYCEMIA UNAWARENESS

Related clinical trials

• AN OPEN-LABEL, FIRST-IN-HUMAN, STUDY EVALUATING THE SAFETY,TOLERABILITY, AND EFFICACY OF VC-02 COMBINATION PRODUCT IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS AND HYPOGLYCEMIA UNAWARENESS
• A ONE-YEAR, MULTICENTER, NON-INTERVENTIONAL, FOLLOW-UP, SAFETY STUDY IN SUBJECTS PREVIOUSLY IMPLANTED WITH VC-02 COMBINATION PRODUCT

View on source registry